Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
Daryl Kai Ann Chia, Raghav Sundar, Guowei Kim, Jia Jun Ang, Jeffrey Lum, Min En Nga, Giap Hean Goh, Ju Ee Seet, Cheng Ean Chee, Hon Lyn Tan, Jingshan Ho, Natalie Y.L. Ngoi, Matilda X. W. Lee, Vaishnavi Muthu, Gloria Chan, Angela S. L. Pang, Yvonne Ang, Joan Choo, Joline S.J. Lim, Jun Liang Teh, Lwin Aung, Yuen Soon, Asim Shabbir, Jimmy Bok Yan So, Wei Peng Yong
Topics & Concepts
MedicineOxaliplatinCapecitabineHazard ratioInternal medicineOncologyClinical endpointGastroenterologySurgical oncologyChemotherapyCancerSurgeryConfidence intervalRandomized controlled trialColorectal cancerGastric Cancer Management and OutcomesIntraperitoneal and Appendiceal MalignanciesGastrointestinal Tumor Research and Treatment